Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02649959 · ClinicalTrials.gov registry record · Phase 3
An Open Label Study of CM-AT for the Treatment of Children With Autism
A Phase 3 study of Autism, sponsored by Curemark.
- Active
- Registry status
- Phase 3
- Development phase
- 405
- Enrollment target
- 20
- Study locations
NCT02649959: Active Phase 3 study of Autism, sponsored by Curemark.
NCT02649959 is a Phase 3 study of Autism that is active but no longer recruiting, run by Curemark. The registered enrollment target is 405 participants, above the 180-participant average among 104 other Autism trials with a reported enrollment target (125% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02649959, a Phase 3 study of Autism, is active but no longer recruiting, sponsored by Curemark.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 405 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, open label extension study evaluating the continued safety and efficacy of CM-AT in pediatric patients with autism with all levels of fecal chymotrypsin.
Conditions Studied
Interventions
- DRUG CM-AT
Study Locations (20)
California
- N.R.C. Research Institute - Orange
- M.I.N.D. Institute (Univ.of California, Davis) - Sacramento
- University of California (U.C.S.F.) - San Francisco
Florida
- Segal Institute For Clinical Research - North Miami
- Advent Health -Lake Mary Pediatrics - Orange City
- A.P.G. Research - Orlando
New Jersey
- Children'S Specialized Hospital - Egg Harbor
- Children's Specialized Hospital - Toms River
- Clinical Research Center of Nj - Voorhees Township
Arizona
- Southwest Autism Research & Resource Center (S.A.R.R.C.) - Phoenix
- University of Arizona, Pediatrics Multidisciplinary Research Unit - Tucson
Louisiana
- Lake Charles Clinical Trials - Lake Charles
- L.S.U. Health Sciences Center - Shreveport
Arkansas
- Arkansas Children'S Hosp. Research Institute (A.C.H.R.I.) - Little Rock
Colorado
- IMMUNOe Research Centers - Centennial
Connecticut
- Yale Child Study Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2015-10 |
| Est. Completion | 2028-01 |
| Phase | Phase 3 |
What the registry record for NCT02649959 still lists
NCT02649959 is an interventional study that assigns participants to a tested intervention. The registered 405 participants enrollment target is mid-sized for trials with a published cap, above the 180-participant average among 104 other Autism trials with a reported enrollment target (125% higher).
The record links to 1 condition, with Autism appearing as the primary indexed condition, and to 1 intervention - of which CM-AT is the first listed.
NCT02649959 names 20 study sites across 12 states, led by California, Florida, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02649959 about?
NCT02649959 is a clinical study titled "An Open Label Study of CM-AT for the Treatment of Children With Autism". This is a Phase III, open label extension study evaluating the continued safety and efficacy of CM-AT in pediatric patients with autism with all levels of fecal chymotrypsin.
What is the current status of trial NCT02649959?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 405 participants. The study started on 2015-10. Estimated completion is 2028-01.
What conditions does trial NCT02649959 study?
This clinical trial studies the following conditions: Autism.
What interventions are being tested in trial NCT02649959?
The interventions under investigation include: CM-AT (DRUG).
Who is sponsoring clinical trial NCT02649959?
This trial is sponsored by Curemark, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02649959 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02649959's enrollment target sits among peer trials
405 8th of 104 higher than 97 of 104 other Autism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pediatric Open-Label Extension Study
COMPLETED · Phase 3
-
Study of Paliperidone ER in Adolescents and Young Adults With Autism
COMPLETED · Phase 3
-
A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms
COMPLETED · Phase 3
-
A Trial of CM-AT in Children With Autism
COMPLETED · Phase 3
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Online Pivotal Response Treatment Training in Autism Spectrum Disorder
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05576350 · 405 participants · NA
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
- NCT07066657 · 405 participants · Phase 1
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- NCT06223360 · 406 participants · Phase 2
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
- NCT06411769 · 406 participants · NA
Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia